



## **SANBIO GRANTED KEY PATENT IN NEW TREATMENT FOR CHRONIC STROKE**

**San Francisco, Calif. — May 15, 2015** —SanBio, a regenerative medicine company leading the way in the development of cell-based biologics targeting neurological disorders, today announced it has been granted a key patent by the United States Patent and Trademark Office (USPTO) covering its proprietary modified stem cells, SB623. SanBio developed SB623 to promote regenerative processes in the central nervous system and provide therapeutic options for chronic stroke and other debilitating neurological disorders. SB623 cells are currently in clinical trials for the treatment of chronic stroke.

United States Patent No. 8,969,078, which covers SB623 cells for all uses, was formally granted on March 3, 2015 and protects the composition of SB623 cells. This patent strengthens SanBio's intellectual property protection for SB623, which previously included protection for methods of making the cells and methods of using the cells to treat various conditions of the central nervous system. SanBio has also received a patent protecting the methods for treating stroke with SB623 cells.

Said Dr. Damien Bates, Chief Medical Officer at SanBio, "Especially during the month of May, National Stroke Awareness month, we reflect on the prevalence of stroke and reaffirm our commitment to developing a therapeutic option for the thousands still suffering from its debilitating effects. This patent protection speaks to our confidence in our technology and the use of SB623 cells to promote regenerative healing for neurological disorders such as stroke."

### **About SanBio**

SanBio is a regenerative medicine company with cell based products in various stages of research, development and clinical trial testing. Its proprietary cell based product, SB623, is in Stage 2 clinical trials for treatment of chronic stroke and is expected to begin Stage 2 clinical trials for treatment of traumatic brain injury later in 2015. Based in Tokyo, the company also has a United States headquarters in San Francisco.

### **Contacts:**

Meredith Gallagher  
(612) 455-1724  
[meredith.gallagher@padillacrt.com](mailto:meredith.gallagher@padillacrt.com)

###